Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxalipiatin

Kana Nakauchi, Hitoshi Kawazoe, Risa Miyajima, Chieko Waizumi, Yuki Rokkaku, Kikue Tsuneoka, Noriko Higuchi, Mitsuko Fujiwara, Yoh Kojima, Yoshihiro Yakushijin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Venous pain induced by oxalipiatin (L-OHP) is a clinical issue related to adherence to the CapeOX regimen. To prevent L-OHP-induced venous pain, we provided nursing care to outpatients who were administered a preheated L-OHP diluted solution using a hot compress. We retrospectively evaluated the risk factors for colorectal cancer patients who had L-OHP-induced phlebitis and venous pain. Furthermore, the preventive effect of nursing care was compared between inpatients and outpatients from January 2010 to March 2012. At the L-OHP administration site, any symptoms were defined as phlebitis, whereas pain was defined as venous pain. A total of 132 treatment courses among 31 patients were evaluated. Multivariate logistic regression analysis revealed that both phlebitis and venous pain were significantly more common in female patients (adjusted odds ratio, 2.357; 95%CI: 1.053-5.418; and adjusted odds ratio, 5.754; 95%CI: 2.119-18.567, respectively). The prevalence of phlebitis and venous pain did not differ between inpatients and outpatients (phlebitis, 61.3% vs 67.7%; venous pain, 29.0% vs 19.4%). These results suggest that administration of L-OHP via a central venous route should be considered in female patients.

Original languageEnglish
Pages (from-to)1397-1400
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume42
Issue number11
Publication statusPublished - 2015 Nov 1
Externally publishedYes

Fingerprint

oxaliplatin
Phlebitis
Pain
Outpatients
Nursing Care
Inpatients
Odds Ratio

Keywords

  • Oxalipiatin
  • Phlebitis
  • Risk factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxalipiatin. / Nakauchi, Kana; Kawazoe, Hitoshi; Miyajima, Risa; Waizumi, Chieko; Rokkaku, Yuki; Tsuneoka, Kikue; Higuchi, Noriko; Fujiwara, Mitsuko; Kojima, Yoh; Yakushijin, Yoshihiro.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 42, No. 11, 01.11.2015, p. 1397-1400.

Research output: Contribution to journalArticle

Nakauchi, K, Kawazoe, H, Miyajima, R, Waizumi, C, Rokkaku, Y, Tsuneoka, K, Higuchi, N, Fujiwara, M, Kojima, Y & Yakushijin, Y 2015, 'Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxalipiatin', Japanese Journal of Cancer and Chemotherapy, vol. 42, no. 11, pp. 1397-1400.
Nakauchi, Kana ; Kawazoe, Hitoshi ; Miyajima, Risa ; Waizumi, Chieko ; Rokkaku, Yuki ; Tsuneoka, Kikue ; Higuchi, Noriko ; Fujiwara, Mitsuko ; Kojima, Yoh ; Yakushijin, Yoshihiro. / Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxalipiatin. In: Japanese Journal of Cancer and Chemotherapy. 2015 ; Vol. 42, No. 11. pp. 1397-1400.
@article{aa9a4f30a03f498da0bb5339de6670ea,
title = "Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxalipiatin",
abstract = "Venous pain induced by oxalipiatin (L-OHP) is a clinical issue related to adherence to the CapeOX regimen. To prevent L-OHP-induced venous pain, we provided nursing care to outpatients who were administered a preheated L-OHP diluted solution using a hot compress. We retrospectively evaluated the risk factors for colorectal cancer patients who had L-OHP-induced phlebitis and venous pain. Furthermore, the preventive effect of nursing care was compared between inpatients and outpatients from January 2010 to March 2012. At the L-OHP administration site, any symptoms were defined as phlebitis, whereas pain was defined as venous pain. A total of 132 treatment courses among 31 patients were evaluated. Multivariate logistic regression analysis revealed that both phlebitis and venous pain were significantly more common in female patients (adjusted odds ratio, 2.357; 95{\%}CI: 1.053-5.418; and adjusted odds ratio, 5.754; 95{\%}CI: 2.119-18.567, respectively). The prevalence of phlebitis and venous pain did not differ between inpatients and outpatients (phlebitis, 61.3{\%} vs 67.7{\%}; venous pain, 29.0{\%} vs 19.4{\%}). These results suggest that administration of L-OHP via a central venous route should be considered in female patients.",
keywords = "Oxalipiatin, Phlebitis, Risk factor",
author = "Kana Nakauchi and Hitoshi Kawazoe and Risa Miyajima and Chieko Waizumi and Yuki Rokkaku and Kikue Tsuneoka and Noriko Higuchi and Mitsuko Fujiwara and Yoh Kojima and Yoshihiro Yakushijin",
year = "2015",
month = "11",
day = "1",
language = "English",
volume = "42",
pages = "1397--1400",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "11",

}

TY - JOUR

T1 - Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxalipiatin

AU - Nakauchi, Kana

AU - Kawazoe, Hitoshi

AU - Miyajima, Risa

AU - Waizumi, Chieko

AU - Rokkaku, Yuki

AU - Tsuneoka, Kikue

AU - Higuchi, Noriko

AU - Fujiwara, Mitsuko

AU - Kojima, Yoh

AU - Yakushijin, Yoshihiro

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Venous pain induced by oxalipiatin (L-OHP) is a clinical issue related to adherence to the CapeOX regimen. To prevent L-OHP-induced venous pain, we provided nursing care to outpatients who were administered a preheated L-OHP diluted solution using a hot compress. We retrospectively evaluated the risk factors for colorectal cancer patients who had L-OHP-induced phlebitis and venous pain. Furthermore, the preventive effect of nursing care was compared between inpatients and outpatients from January 2010 to March 2012. At the L-OHP administration site, any symptoms were defined as phlebitis, whereas pain was defined as venous pain. A total of 132 treatment courses among 31 patients were evaluated. Multivariate logistic regression analysis revealed that both phlebitis and venous pain were significantly more common in female patients (adjusted odds ratio, 2.357; 95%CI: 1.053-5.418; and adjusted odds ratio, 5.754; 95%CI: 2.119-18.567, respectively). The prevalence of phlebitis and venous pain did not differ between inpatients and outpatients (phlebitis, 61.3% vs 67.7%; venous pain, 29.0% vs 19.4%). These results suggest that administration of L-OHP via a central venous route should be considered in female patients.

AB - Venous pain induced by oxalipiatin (L-OHP) is a clinical issue related to adherence to the CapeOX regimen. To prevent L-OHP-induced venous pain, we provided nursing care to outpatients who were administered a preheated L-OHP diluted solution using a hot compress. We retrospectively evaluated the risk factors for colorectal cancer patients who had L-OHP-induced phlebitis and venous pain. Furthermore, the preventive effect of nursing care was compared between inpatients and outpatients from January 2010 to March 2012. At the L-OHP administration site, any symptoms were defined as phlebitis, whereas pain was defined as venous pain. A total of 132 treatment courses among 31 patients were evaluated. Multivariate logistic regression analysis revealed that both phlebitis and venous pain were significantly more common in female patients (adjusted odds ratio, 2.357; 95%CI: 1.053-5.418; and adjusted odds ratio, 5.754; 95%CI: 2.119-18.567, respectively). The prevalence of phlebitis and venous pain did not differ between inpatients and outpatients (phlebitis, 61.3% vs 67.7%; venous pain, 29.0% vs 19.4%). These results suggest that administration of L-OHP via a central venous route should be considered in female patients.

KW - Oxalipiatin

KW - Phlebitis

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=84960119583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960119583&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 1397

EP - 1400

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 11

ER -